David FisherOur #STOPCAP #IPDMA of #docetaxel for advanced #prostateCancer #mHSPC came out this week in #LancetOncology!
Very excited about this: result of tremendous collaborative effort to obtain harmonized trial data, apply meticulous checking & processing, and carry out high-quality statistical analysis. Aim was to clarify patterns of survival within patient subgroups most & least likely to benefit.